INTRODUCTION: Cerebral blood volume (CBV) measurement by flat panel detector CT (FPCT) in the angiography suite seems to be a promising tool for patient management during endovascular therapies. A steady state of contrast agent distribution is mandatory during acquisition for accurate FPCT CBV assessment. To the best of our knowledge, this was the first time that steady-state parameters were studied in clinical practice. METHODS: Before the CBV study, test injections were performed and analyzed to determine a customized acquisition delay from injection for each patient. Injection protocol consisted in the administration of 72 mL of contrast agent material at the injection rate of 4.0 mL/s followed by a saline flush bolus at the same injection rate. Peripheral or central venous accesses were used depending on their availability. Twenty-four patients were treated for different types of neurovascular diseases. Maximal attenuation, steady-state length, and steady-state delay from injection were derived from the test injections' time attenuation curves. RESULTS: With a 15 % threshold from maximum attenuation values, average steady-state duration was less than 10 s. Maximum average steady-state duration with minimal delay variation was obtained with central injection protocols. CONCLUSION: With clinically acceptable contrast agent volumes, steady state is a brief condition; thus, fast rotation speed acquisitions are needed. The use of central injections decreases the variability of steady-state's delay from injection. Further studies are needed to optimize and standardize injection protocols to allow a larger diffusion of the FPCT CBV measurement during endovascular treatments.
INTRODUCTION: Cerebral blood volume (CBV) measurement by flat panel detector CT (FPCT) in the angiography suite seems to be a promising tool for patient management during endovascular therapies. A steady state of contrast agent distribution is mandatory during acquisition for accurate FPCT CBV assessment. To the best of our knowledge, this was the first time that steady-state parameters were studied in clinical practice. METHODS: Before the CBV study, test injections were performed and analyzed to determine a customized acquisition delay from injection for each patient. Injection protocol consisted in the administration of 72 mL of contrast agent material at the injection rate of 4.0 mL/s followed by a saline flush bolus at the same injection rate. Peripheral or central venous accesses were used depending on their availability. Twenty-four patients were treated for different types of neurovascular diseases. Maximal attenuation, steady-state length, and steady-state delay from injection were derived from the test injections' time attenuation curves. RESULTS: With a 15 % threshold from maximum attenuation values, average steady-state duration was less than 10 s. Maximum average steady-state duration with minimal delay variation was obtained with central injection protocols. CONCLUSION: With clinically acceptable contrast agent volumes, steady state is a brief condition; thus, fast rotation speed acquisitions are needed. The use of central injections decreases the variability of steady-state's delay from injection. Further studies are needed to optimize and standardize injection protocols to allow a larger diffusion of the FPCT CBV measurement during endovascular treatments.
Authors: Filippo Cademartiri; Aad van der Lugt; Giacomo Luccichenti; Paolo Pavone; Gabriel P Krestin Journal: J Comput Assist Tomogr Date: 2002 Jul-Aug Impact factor: 1.826
Authors: T Struffert; Y Deuerling-Zheng; T Engelhorn; S Kloska; P Gölitz; M Köhrmann; S Schwab; C M Strother; A Doerfler Journal: AJNR Am J Neuroradiol Date: 2011-12-29 Impact factor: 3.825
Authors: T Struffert; Y Deuerling-Zheng; S Kloska; T Engelhorn; C M Strother; W A Kalender; M Köhrmann; S Schwab; A Doerfler Journal: AJNR Am J Neuroradiol Date: 2010-04-08 Impact factor: 3.825
Authors: P Mordasini; M El-Koussy; C Brekenfeld; G Schroth; U Fischer; J Beck; J Gralla Journal: AJNR Am J Neuroradiol Date: 2011-09-29 Impact factor: 3.825
Authors: Pamela W Schaefer; Kit Mui; Shahmir Kamalian; Raul G Nogueira; R Gilberto Gonzalez; Michael H Lev Journal: Stroke Date: 2009-06-11 Impact factor: 7.914